Last reviewed · How we verify

NCT03014050: BEST

Bio Electro Stimulation Therapy for Parkinson's Disease

Completed EARLY_PHASE1 Last updated 3 April 2020
What this trial tests

EARLY_PHASE1 trial testing e-Tapper TT-R1 in Parkinson Disease in 21 participants. Completed in 1 June 2019.

Timeline
22 September 2017
Primary endpoint
1 June 2019
1 June 2019

Quick facts

Lead sponsorBoston University
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment21
Start date22 September 2017
Primary completion1 June 2019
Estimated completion1 June 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Boston University

Who can join

Adults 50 to 75, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction and non-motor symptoms. Here, the investigators propose in a pilot device feasibility trial to examine whether "Bio Electro Stimulation Therapy" (B.E.S.T.) with a small, non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hand can ameliorate some of the symptoms of PD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other Boston University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03014050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing